Condition: ACUTE LYMPHOBLASTIC LEUKEMIA · Sponsor: Pfizer
This prospective, randomized, multicenter, open-label Phase 2 study is designed to evaluate the superiority of InO monotherapy vs ALLR3 after 1 cycle of induction treatment in paediatric participants (between 1 and \<18 years) with High Risk (HR) or very high risk (VHR) first bone marrow relapse CD22-positive BCP ALL, and to evaluate the safety and tolerability, PK and long-term efficacy. Treatment with study intervention will end after induction therapy; follow-up will continue for up to 5 years from randomization.
This description comes directly from the study's public registry record.
Pfizer CT.gov Call Center · 1-800-718-1021 · ClinicalTrials.gov_Inquiries@pfizer.com
Always discuss trial participation with your own doctor first.
| St. Anna Kinderspital | Vienna, Austria | Recruiting |
| Cliniques universitaires Saint-Luc | Brussels, Bruxelles-capitale, Région de, Belgium | Recruiting |
| UZ Gent | Ghent, Oost-vlaanderen, Belgium | Recruiting |
| UZ Leuven | Leuven, Vlaams-brabant, Belgium | Recruiting |
| Detska nemocnice FN Brno | Brno, Brno-město, Czechia | Recruiting |
| Fakultni Nemocnice Motol a Homolka | Prague, Czechia | Recruiting |
| Rigshospitalet | Copenhagen, Capital Region, Denmark | Recruiting |
| Helsinki university hospital | Helsinki, Finland | Recruiting |
| Centre Hospitalier Universitaire de Nice - Hôpital l'Archet | Nice, Alpes-maritimes, France | Recruiting |
| CHU Strasbourg-Hautepierre, Service d'hematologie oncologie pediatrique, pediatrie 3 | Strasbourg, Alsace, France | Recruiting |
| Bordeaux University Hospital - Pellegrin | Bordeaux, Aquitaine, France | Recruiting |
| CHU de Toulouse - Hôpital des Enfants - Hemato-Immuno-Oncologie | Toulouse, Haute-garonne, France | Recruiting |
+ 56 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05748171